Graham Parry
Stock Analyst at Citi
(2.03)
# 3,261
Out of 5,010 analysts
233
Total ratings
56.8%
Success rate
0.3%
Average return
Main Sectors:
Stocks Rated by Graham Parry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 17,800p | 12,428p | +43.22% | 15 | Sep 29, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 2,100p | 1,856p | +13.15% | 54 | Sep 15, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Buy | CHF 135.00 | CHF 120.92 | +11.64% | 54 | Sep 9, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Buy | n/a | $349.30 | - | 5 | Mar 10, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €85.00 → €80.00 | €71.47 | +11.94% | 40 | Feb 20, 2026 | |
| SNY Sanofi | Reiterated: Buy | n/a | $40.74 | n/a | 17 | Jan 31, 2025 | |
| GSK GSK plc | Reiterated: Sell | $19 | $49.35 | n/a | 23 | Dec 6, 2024 | |
| NVS Novartis AG | Rated: Hold | $118 → $130 | $145.71 | n/a | 17 | Sep 11, 2024 | |
| BME: GRF Grifols, S.A. | Initiated Coverage: Buy | €20.00 | €9.49 | n/a | 1 | Sep 12, 2023 | |
| LON: HLN Haleon plc | Reiterated: Buy | 358p → 625p | 337p | n/a | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $88 | $151.28 | n/a | 1 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $50 | $28.72 | n/a | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $35.57 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $34 | $52.25 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $5.59 | n/a | 1 | Oct 26, 2017 |
AstraZeneca PLC
Sep 29, 2026
Reiterated: Buy
Price Target: 17,800p
Current: 12,428p
Upside: +43.22%
GSK plc
Sep 15, 2026
Reiterated: Hold
Price Target: 2,100p
Current: 1,856p
Upside: +13.15%
Novartis AG
Sep 9, 2026
Reiterated: Buy
Price Target: CHF 135.00
Current: CHF 120.92
Upside: +11.64%
Roche Holding AG
Mar 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $349.30
Upside: -
Sanofi
Feb 20, 2026
Reiterated: Hold
Price Target: €85.00 → €80.00
Current: €71.47
Upside: +11.94%
Sanofi
Jan 31, 2025
Reiterated: Buy
Price Target: n/a
Current: $40.74
Upside: n/a
GSK plc
Dec 6, 2024
Reiterated: Sell
Price Target: $19
Current: $49.35
Upside: n/a
Novartis AG
Sep 11, 2024
Rated: Hold
Price Target: $118 → $130
Current: $145.71
Upside: n/a
Grifols, S.A.
Sep 12, 2023
Initiated Coverage: Buy
Price Target: €20.00
Current: €9.49
Upside: n/a
Haleon plc
Mar 7, 2023
Reiterated: Buy
Price Target: 358p → 625p
Current: 337p
Upside: n/a
Mar 3, 2023
Reiterated: Hold
Price Target: $88
Current: $151.28
Upside: n/a
Feb 28, 2023
Reiterated: Hold
Price Target: $50
Current: $28.72
Upside: n/a
Sep 10, 2018
Downgraded: Sell
Price Target: n/a
Current: $35.57
Upside: n/a
Sep 10, 2018
Downgraded: Hold
Price Target: $34
Current: $52.25
Upside: n/a
Oct 26, 2017
Downgraded: Sell
Price Target: n/a
Current: $5.59
Upside: n/a